MTOR and lung carcinoma: Another downstream regulator of the PI3K pathway, the mammalian target of rapamycin (mTOR), was found to be mutated in more than 30% of 188 lung adenocarcinomas [23] and is also frequently activated in lung cancer cell lines, and especially in these harboring genetic mutations [54,55,56].